2023
Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study.
Böhme T, Zeller T, Shishehbor M, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh S, Kashyap V, Pietras C, Tirziu D, Beschorner U, Krishnan P, Niazi K, Wali A, Lansky A. Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study. Journal Of Endovascular Therapy 2023, 15266028231179589. PMID: 37314243, DOI: 10.1177/15266028231179589.Peer-Reviewed Original ResearchLutonix drug-coated balloonDrug-coated balloonsPrimary safety endpointDM statusFemoropopliteal diseaseDiabetes mellitusSafety endpointFemoropopliteal lesionsSimilar safetyHigh-risk patient populationFemoropopliteal artery lesionsIschemic rest painNon-DM patientsSymptomatic femoropopliteal lesionsPrimary efficacy endpointMajor adverse eventsTherapy of choiceDrug-Coated BalloonMajor amputationRest painEfficacy endpointPrimary patencyAdverse eventsArtery lesionsDiabetes status
2014
Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus Analysis From 18 Pooled Randomized Trials
Kedhi E, Généreux P, Palmerini T, McAndrew T, Parise H, Mehran R, Dangas G, Stone G. Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus Analysis From 18 Pooled Randomized Trials. Journal Of The American College Of Cardiology 2014, 63: 2111-2118. PMID: 24632279, DOI: 10.1016/j.jacc.2014.01.064.Peer-Reviewed Original ResearchConceptsDiabetes mellitusRepeat revascularizationMyocardial infarctionLesion complexityStent outcomesCardiac deathType A/B1 lesionsType B2/C lesionsB2/C lesionsPropensity score-matched groupsCoronary lesion complexityTarget vessel revascularizationPatient-level dataB1 lesionsNoncomplex lesionsVessel revascularizationDiabetic statusC lesionsDES eraRandomized trialsRisk factorsTarget lesionsDES safetyTreatment outcomesBaseline differences
2011
Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus
Stone G, Kedhi E, Kereiakes D, Parise H, Fahy M, Serruys P, Smits P. Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus. Circulation 2011, 124: 893-900. PMID: 21824922, DOI: 10.1161/circulationaha.111.031070.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsPercutaneous coronary interventionEverolimus-eluting stentsDiabetes mellitusLesion revascularizationCoronary interventionStent thrombosisMyocardial infarctionStent typeIschemia-driven target lesion revascularizationEnd pointDifferential clinical responseXIENCE V EverolimusEfficacy end pointTarget lesion revascularizationTreatment of patientsCoronary stent systemSignificant differencesEverolimus-ElutingCoronary revascularizationEfficacy outcomesClinical responseDiabetic statusDiabetic patientsClinical outcomesImpact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Witzenbichler B, Mehran R, Guagliumi G, Dudek D, Huber K, Kornowski R, Stuckey T, Fahy M, Parise H, Stone G. Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 760-768. PMID: 21777884, DOI: 10.1016/j.jcin.2011.04.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyDiabetes MellitusDose-Response Relationship, DrugDouble-Blind MethodElectrocardiographyFemaleFollow-Up StudiesHirudinsHumansHypoglycemic AgentsMaleMiddle AgedMyocardial InfarctionPeptide FragmentsProspective StudiesRecombinant ProteinsStentsSurvival RateTime FactorsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionHORIZONS-AMI trialDiabetes mellitusDiabetic patientsMyocardial infarctionPrimary PCIMajor adverse cardiac eventsIIb/IIIa inhibitorsEffectiveness of bivalirudinEfficacy of bivalirudinAdverse cardiac eventsAcute coronary syndromeElevation myocardial infarctionPercutaneous coronary interventionAcute myocardial infarctionMajor bleedingCardiac mortalityCoronary syndromeAnticoagulant therapyCardiac eventsCoronary interventionCardiac deathUnfractionated heparinIMPACT OF BIVALIRUDIN PROCEDURAL ANTICOAGULATION IN PATIENTS WITH DIABETES MELLITUS AND ACUTE MYOCARDIAL INFARCTION UNDERGOING PRIMARY ANGIOPLASTY: 3-YEAR RESULTS FROM THE HORIZONS AMI TRIAL
Witzenbichler B, Mehran R, Guagliumi G, Desaga M, Kochman J, Nilsen D, Finkelstein A, Mosseri M, Parise H, Cristea E, Stone G. IMPACT OF BIVALIRUDIN PROCEDURAL ANTICOAGULATION IN PATIENTS WITH DIABETES MELLITUS AND ACUTE MYOCARDIAL INFARCTION UNDERGOING PRIMARY ANGIOPLASTY: 3-YEAR RESULTS FROM THE HORIZONS AMI TRIAL. Journal Of The American College Of Cardiology 2011, 57: e1801. DOI: 10.1016/s0735-1097(11)61801-9.Peer-Reviewed Original Research
2005
Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus
Wilson P, D’Agostino R, Parise H, Sullivan L, Meigs J. Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus. Circulation 2005, 112: 3066-3072. PMID: 16275870, DOI: 10.1161/circulationaha.105.539528.Peer-Reviewed Original ResearchConceptsCoronary heart diseaseMetabolic syndromeCardiovascular diseaseRelative riskAge-adjusted relative riskType 2 diabetes mellitusPopulation attributable risk estimatesNew cardiovascular diseaseMetabolic syndrome traitsMiddle-aged adultsDiabetes mellitusIncident casesHeart diseaseNew T2DMT2DMType 2SyndromeEvent ratesRisk estimatesDiseaseSyndrome traitsMellitusWomenMenRisk
2002
Overweight and Obesity as Determinants of Cardiovascular Risk: The Framingham Experience
Wilson P, D'Agostino R, Sullivan L, Parise H, Kannel W. Overweight and Obesity as Determinants of Cardiovascular Risk: The Framingham Experience. JAMA Internal Medicine 2002, 162: 1867-1872. PMID: 12196085, DOI: 10.1001/archinte.162.16.1867.Peer-Reviewed Original ResearchConceptsAge-adjusted relative riskBody mass indexCoronary heart diseasePopulation attributable riskRelative riskCardiovascular diseaseCardiovascular sequelaeAngina pectorisExcess weightAttributable riskHeart diseaseOverweight statusRisk factorsCardiovascular disease risk factorsHighest population-attributable riskNew cardiovascular diseaseDisease risk factorsFramingham Heart Study participantsNormal-weight personsDisease end pointsNew hypertensionCardiovascular riskDiabetes mellitusPrimary outcomeMass index